Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359876 · ClinicalTrials.gov registry record
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
A clinical trial of Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 16,000
- Enrollment target
- 1
- Study location
NCT03359876 is a study of Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 16,000 participants, above the 2,918-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (448% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03359876, a study of Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 16,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be conducted in the US Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Warfarin sodium
Study Locations (1)
New Jersey
- US Truven MarketScan - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,000 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03359876
The ClinicalTrials.gov registry entry for NCT03359876 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,918-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (448% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03359876 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03359876 about?
NCT03359876 is a clinical study titled "Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction". The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be...
What is the current status of trial NCT03359876?
This trial is currently completed. The enrollment target is 16,000 participants. The study started on 2017-12-01. Estimated completion is 2019-03-29.
What conditions does trial NCT03359876 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03359876?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Warfarin sodium (DRUG).
Who is sponsoring clinical trial NCT03359876?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03359876 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.